Publications by authors named "L Biener"
Background: Patients with severe asthma (SA) benefit from biologic therapy substantially. However, the impact of smoking-related comorbidities remains unclear due to the exclusion of patients with ≥10 pack-years from asthma studies. Our aim was to examine the effects of emphysema on biologic treatment response in SA in this retrospective cohort study.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the relationship between eosinophils and changes in arteries among asthma patients, given that both conditions are linked to inflammation but previous mediators weren't well understood.
- - A total of 100 asthma patients were assessed, comparing those with low (< 300/µl) and high (≥ 300/µl) eosinophil blood counts, with findings showing that high eosinophil counts correlated with more severe asthma symptoms and increased arterial stiffness.
- - Results indicated that higher eosinophil levels were associated with reduced radial strain in the carotid arteries, suggesting potential support for the idea that eosinophils could play a role in the development of atherosclerosis.
Introduction: Asthma patients with a smoking history are usually excluded from asthma trials to exclude smoking-related comorbidities like chronic obstructive pulmonary disease (COPD). Therefore, little is known about the efficacy of biologic therapy in asthma patients with reduced diffusing capacity of the lungs for carbon monoxide (DLCO).
Methods: This study aimed to assess the response to biologic therapy in asthma patients with reduced DLCO.
Iron deficiency (ID) is common in patients with pulmonary arterial hypertension and has been associated with increased morbidity and mortality. We aimed to evaluate the therapeutic effects of iron supplementation in iron deficient patients with group 1 to 4 pulmonary hypertension (PH). A total of 85 PH patients (mean age 69.
View Article and Find Full Text PDFReal-World Data on Tezepelumab in Patients With Severe Asthma in Germany.
J Allergy Clin Immunol Pract
September 2024
Background: Tezepelumab is a novel biologic blocking thymic stromal lymphopoetin, approved for severe asthma irrespective of biomarker levels or phenotype.
Objective: To characterize a real-world tezepelumab patient cohort and the efficacy among various asthma phenotypes.
Methods: We performed a retrospective, multicenter study on patients with severe asthma initiating tezepelumab.